— Company Updates Guidance and Clinical Development Timeline in Response to the COVID-19 Global Pandemic — — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md., May 5, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas […]
— Received FDA Guidance Following Type-C Meeting to Conduct a Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic HCT Recipients; Enrollment Expected in Q2 2020 — — Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010 for the Treatment of IBS-C — Conference Call Today at 4:30 p.m. (ET) — ROCKVILLE, Md.,
Synthetic Biologics Reports 2019 Year End Operational Highlights and Financial Results Read More »
ROCKVILLE, Md., Feb. 7, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the NYSE American LLC (the “Exchange”) has accepted the Company’s plan of compliance (the “Plan”) for
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American Read More »
ROCKVILLE, Md., Feb. 4, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that Steven A. Shallcross, Chief Executive and Financial Officer, is scheduled to present at the BIO CEO &
Synthetic Biologics to Present at the 2020 BIO CEO & Investor Conference Read More »
ROCKVILLE, Md., Jan. 7, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the receipt of official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C
ROCKVILLE, Md., Nov. 27, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the “Exchange”), the Company’s current listing exchange, stating
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan Read More »
Webcast 3 2019 Quarterly Results PDF Release AUDIO Webcast PDF HTML 10-Q Filing ZIP XLS HTML XBRL
Third Quarter 2019 Operational Highlights and Financial Results Conference Call Read More »
— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C — — Conference Call Today, November 4, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Nov. 4, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent
— Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET — ROCKVILLE, Md., Oct. 28, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company intends
— Issuance of New Patent and Allowance of Patent Application Diversifies SYN-010 Protection in US — ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office
